Novo Nordisk has launched its Wegovy weight-loss pill in the US, sparking a new price war. The once-daily pill is the first GLP-1 tablet on the market and costs far less than injectable alternatives. Self-paying patients can access starter doses for $149 a month, with insured patients paying from $25. The company aims to regain market share lost to rivals such as Eli Lilly, whose injectable drugs dominate the sector. The pill is now available through major US pharmacies and telehealth providers, with wider rollout planned. Novo hopes the needle-free option will attract new patients and revive growth after a difficult year.
Trending
- Epstein assistant Groff faces explosive scrutiny
- Cuba sanctions UN warning urges immediate removal
- Trump attorney general nominee Todd Blanche pick
- Trump NBA finals boos rock Madison Square Garden
- Beecle: Official Online Shop Launch Marks New Entry Into the Cosmetics Industry
- Probiotic foods dietitian reveals gut fix
- AI stock market pause shocks Wall Street
- Alderney ferry subsidy service cancelled after tender
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition
Andrew Rogers
Andrew Rogers is a freelance journalist based in Chicago, USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He graduated with a degree in Journalism from the University of Florida. Over the years, he has contributed to leading outlets such as The New York Times, CNN, and Reuters. Recognized for his sharp reporting and thoughtful analysis, Andrew delivers accurate and timely news that keeps readers updated on key national and global developments.
Add A Comment